Amanda J. Kennedy

Amanda J. Kennedy

Auto-generated profile, based on publicly available information

Amanda J. Kennedy

CHARM Therapeutics Ltd., B900, Babraham Research Campus, Cambridge, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Pharmacological Reviews
Verified
Journal Article
Open access
PDF file
AKAmanda J. Kennedy
Amanda J. Kennedy
ADAnthony P. Davenport
Anthony P. Davenport
Chemerin, a chemoattractant protein and adipokine, has been identified as the endogenous ligand for a G protein–coupled receptor encoded by the gene CMKLR1 (also known as ChemR23), and as a consequence the receptor protein was renamed the chemerin receptor in 2013. Since then, chemerin has been identified as the endogenous ligand for a second G protein–coupled receptor, encoded by the gene GPR1. Therefore, the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification recommends that the official name of the receptor protein for chemokine-like receptor 1 (CMKLR1) is chemerin receptor 1, and G protein–coupled receptor 1 is chemerin receptor 2 to follow the convention of naming the receptor protein after the endogenous ligand. Chemerin receptor 1 and chemerin receptor 2 can be abbreviated to Chemerin1 and Chemerin2, respectively. Chemerin requires C-terminal processing for activity, and human chemerin21–157 is reported to be the most active form, with peptide fragments derived from the C terminus biologically active at both receptors. Small-molecule antagonist, CCX832, selectively blocks CMKLR1, and resolvin E1 activation of CMKLR1 is discussed. Activation of both receptors by chemerin is via coupling to Gi/o, causing inhibition of adenylyl cyclase and increased Ca2+ flux. Receptors and ligand are widely expressed in humans, rats, and mice, and both receptors share ∼80% identity across these species. CMKLR1 knockout mice highlight the role of this receptor in inflammation and obesity, and similarly, GPR1 knockout mice exhibit glucose intolerance. In addition, the chemerin receptors have been implicated in cardiovascular disease, cancer, steroidogenesis, human immunodeficiency virus replication, and neurogenerative disease.

3 October 2016 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
AKAmanda J. Kennedy
Amanda J. Kennedy
PYPei ran Yang Yang
Pei ran Yang Yang
CRCai Read
Cai Read
RKRhoda E. Kuc
Rhoda E. Kuc
LYLucy Yang
Lucy Yang
ADAnthony P. Davenport
Anthony P. Davenport
Background: Circulating levels of chemerin are significantly higher in hypertensive patients and positively correlate with blood pressure. Chemerin activates chemokine‐like receptor 1 ( CMKLR 1 or ChemR23) and is proposed to activate the “orphan” G‐protein‐coupled receptor 1 ( GPR 1), which has been linked with hypertension. Our aim was to localize chemerin, CMKLR 1, and GPR 1 in the human vasculature and determine whether 1 or both of these receptors mediate vasoconstriction. Methods and Results: Using immunohistochemistry and molecular biology in conduit arteries and veins and resistance vessels, we localized chemerin to endothelium, smooth muscle, and adventitia and found that CMKLR 1 and GPR 1 were widely expressed in smooth muscle. C9 (chemerin149–157) contracted human saphenous vein ( pD 2 =7.30±0.31) and resistance arteries ( pD 2 =7.05±0.54) and increased blood pressure in rats by 9.1±1.0 mm Hg at 200 nmol. Crucially, these in vitro and in vivo vascular actions were blocked by CCX 832, which we confirmed to be highly selective for CMKLR 1 over GPR 1. C9 inhibited cAMP accumulation in human aortic smooth muscle cells and preconstricted rat aorta, consistent with the observed vasoconstrictor action. Downstream signaling was explored further and, compared to chemerin, C9 showed a bias factor=≈5000 for the G i protein pathway, suggesting that CMKLR 1 exhibits biased agonism. Conclusions: Our data suggest that chemerin acts at CMKLR 1, but not GPR 1, to increase blood pressure. Chemerin has an established detrimental role in metabolic syndrome, and these direct vascular actions may contribute to hypertension, an additional risk factor for cardiovascular disease. This study provides proof of principle for the therapeutic potential of selective CMKLR 1 antagonists.

15 September 2016 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
RCRafael Custódio
Rafael Custódio
CMChristopher J. McLean
Christopher J. McLean
ASAndrew E. Scott
Andrew E. Scott
JLJonathan Lowther
Jonathan Lowther
AKAmanda Kennedy
Amanda Kennedy
ABAlan R. Brown
Alan R. Brown
Summary: Sphingosine‐1‐phosphate (S1P), a bioactive sphingolipid metabolite, plays a critical role in the orchestration of immune responses. S1P levels within the mammalian host are tightly regulated, in part through the activity of S1P lyase (S1PL) which catalyses its irreversible degradation. Herein, we describe the identification and characterization of secreted S1PL orthologues encoded by the facultative intracellular bacteria Burkholderia pseudomallei and Burkholderia thailandensis. These bacterial orthologues exhibited S1PL enzymatic activity, functionally complemented an S1PL‐deficient yeast strain and conferred resistance to the antimicrobial sphingolipid D‐erythro‐sphingosine. We report that secretion of these bacterial S1PLs is pH‐dependent, and is observed during intracellular infection. S1PL‐deficient mutants displayed impaired intracellular replication in murine macrophages (associated with an inability to evade the maturing phagosome) and were significantly attenuated in murine and larval infection models. Furthermore, treatment of Burkholderia‐infected macrophages with either S1P or a selective agonist of S1P receptor 1 enhanced bacterial colocalisation with LAMP‐1 and reduced their intracellular survival. In summary, our studies confirm bacterial‐encoded S1PL as a critical virulence determinant of B. pseudomallei and B. thailandensis, further highlighting the pivotal role of S1P in host‐pathogen interactions. In addition, our data suggest that S1P pathway modulators have potential for the treatment of intracellular infection.

16 October 2018 in ACS Pharmacology & Translational Science
Verified
Journal Article
Open access
AKAmanda J. Kennedy
Amanda J. Kennedy
Flavio BallanteFlavio Ballante
Flavio Ballante
JJJohan R. Johansson
Johan R. Johansson
GMGraeme Milligan
Graeme Milligan
LSLinda Sundström
Linda Sundström
JCJens Carlsson
Jens Carlsson
Protease-activated receptor 2 (PAR2) is a G protein-coupled receptor that is activated by proteolytic cleavage of its N-terminus. The unmasked N-terminal peptide then binds to the transmembrane bundle, leading to activation of intracellular signaling pathways associated with inflammation and cancer. Recently determined crystal structures have revealed binding sites of PAR2 antagonists, but the binding mode of the peptide agonist remains unknown. In order to generate a model of PAR2 in complex with peptide SLIGKV, corresponding to the trypsin-exposed tethered ligand, the orthosteric binding site was probed by iterative combinations of receptor mutagenesis, agonist ligand modifications and data-driven structural modeling. Flexible-receptor docking identified a conserved binding mode for agonists related to the endogenous ligand that was consistent with the experimental data and allowed synthesis of a novel peptide (1-benzyl-1H[1,2,3]triazole-4-yl-LIGKV) with higher functional potency than SLIGKV. The final model may be used to understand the structural basis of PAR2 activation and in virtual screens to identify novel PAR2 agonist and competitive antagonists. The combined experimental and computational approach to characterize agonist binding to PAR2 can be extended to study the many other G protein-coupled receptors that recognize peptides or proteins.

1 January 2017 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
CMChristopher J. McLean
Christopher J. McLean
JMJon Marles-Wright
Jon Marles-Wright
RCRafael Custodio
Rafael Custodio
JLJonathan Lowther
Jonathan Lowther
AKAmanda J. Kennedy
Amanda J. Kennedy
DCDominic J. Campopiano
Dominic J. Campopiano
Christopher J. McLean, Jon Marles-Wright, Rafael Custodio, Jonathan Lowther, Amanda J. Kennedy, Jacob Pollock, David J. Clarke, Alan R. Brown, Dominic J. Campopiano

28 January 2026 in Communications Biology
Verified
Journal Article
Open access
PDF file
CFCatherine T. Fletcher
Catherine T. Fletcher
AMAbigail A. Mornement
Abigail A. Mornement
CBCharlotte Barrett
Charlotte Barrett
PCPeter Canning
Peter Canning
PRPrakash Rucktooa
Prakash Rucktooa
AKAmanda J. Kennedy
Amanda J. Kennedy
Werner syndrome helicase (WRN) is a RecQ-family DNA helicase essential for genome maintenance and is a synthetic lethal target in microsatellite instability-high (MSI-H) cancers. Despite its therapeutic promise, the conformational dynamics that enable WRN to unwind DNA, and how inhibitors disrupt this activity, remains poorly understood. Here, we present crystal structures of apo WRN and WRN bound to single-stranded DNA (ssDNA), capturing key conformations in the helicase catalytic cycle. These structures reveal how WRN engages DNA through conserved polar and aromatic interactions, and how domain rearrangements, including an ordering of the aromatic-rich loop (ARL), drive directional translocation. Biochemical and biophysical data demonstrate how nucleotide and inhibitor binding remodel these conformations and suggest that known clinical inhibitors (HRO761 and VVD-133214) function by locking WRN in inactive, ‘off-DNA’ states. Resistance emerged rapidly in vitro, through acquired point mutations as well as altered WRN expression. Together, our findings provide a structural framework for the WRN structural cycle and support the development of next-generation ‘on-DNA’ inhibitors to overcome resistance.